<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:department>Chemistry</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/15E31F79-C231-4D16-8554-2014DAB8C520"><gtr:id>15E31F79-C231-4D16-8554-2014DAB8C520</gtr:id><gtr:firstName>Bernard</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Rawlings</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FD017270%2F1"><gtr:id>896F37E7-2379-4310-9B11-8D08BE5CE8E7</gtr:id><gtr:title>New analogues of amphotericin B generated by gene disruption</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/D017270/1</gtr:grantReference><gtr:abstractText>Amphotericin B is a complex natural (polyene) product and clinically important antifungal antibiotic produced by a soil bacterium. In recent years there has been a dramatic increase in life threatening invasive fungal infections. Most of the common treatments have been rendered useless by the emergence of multidrug resistance in fungal pathogens. One of the few remaining reliable drugs is amphotericin B, that is active against most fungal strains and because resistance has not emerged as a problem even after over forty years of clinical use. However, this antibiotic has dangerous side effects that limit its use. Many attempts have been made to generate analogues of amphotericin B that retain antifungal activity with much diminished human toxicity. The structural complexity of amphotericin has made conventional chemical derivatisation very difficult, yet several useful analogues have been generated, but the expense of their chemical preparation renders them impractical for clinical use. However, their existence demonstrates that analogues with improved therapeutic potential do exist. In Leicester, we have studied Nature's 'molecular architecture' to find out how these intricate molecules are assembled from very small building blocks. We now know what 'bricks and mortar' are used, and the order in which they are put together, to obtain the final product. Recent advances in molecular biology now enables the exploitation of this understanding to produce a wide range of analogues. Dr Caffrey in Dublin has generated a series of mutants (a bit is missing from the DNA blueprint) that no longer produce amphotericin B. One mutant produces amphotericin lacking in a hydroxyl group. Another mutant produces the core part of the molecule, but no longer has a sugar unit attached to its side. A third set of mutants have several bits missing. We will examine all these mutants to determine the actual structures produced, and the effect of these omissions on antifungal astivity. We will generate a mutant that not only is missing the sugar unit, but has the DNA blueprint added, that will add to our molecule, a different sugar unit. The long term aim of this research is to generate commercially viable biologically produced analogues of amphotericin B that, retain its antifungal activity with much reduced human toxicity, this will save lives.</gtr:abstractText><gtr:technicalSummary>Dr Caffrey in University College, Dublin has sequenced the gene cluster in Streptomyces nodosus responsible for the biosynthesis of amphotericin and has now generated several mutants that produce polyenes in good yield, varying from ca 10 to 250 mg/L mixed polyenes. This proposal is focussed upon structural determination of these polyene products, and obtaining them in large enough pure quantities to examine their ability to form pores in membranes, or in a range of bioassays. The first priority is to obtain and characterise the major polyene produced by the amphL mutant, deficient in the cytochrome P-450 oxidation at C-8, a late biosynthetic step. The second priority is determining the major products of amphDIII, which is unable to make the amino sugar mycosamine, and produces large quantities (250 mg/L) of mixed aglycone polyene products, including an epimer of an expected biosynthetic amphoteronolide intermediate. Determination of the stereostructure of this compound, will provide information about the early PKS modules, and their stereochemical flexibility. A third group of mutants are deficient in the cytochrome p-450 that oxidises the C-16 methyl to the carboxyl group. Isolation and product characterisation firstly allows rigorous gene mapping of the amphNM genes. The longer term aim of this work is through a greater understanding of polyene biosynthesis, generate commercially viable analogues of amphotericin B that retain its antrifungal activity, but with considerably reduced human toxicity.</gtr:technicalSummary><gtr:fund><gtr:end>2009-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2006-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>368321</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Production and Isolation of Amphotericin B Analogues in vivo</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>17214983-C62C-4975-900F-58B32832D62D</gtr:id><gtr:impact>Oral presentation at 'Drugs from Natural Sources IV', New Hall, Cambreidge, UK, 7-8th April 2008

RSC Biological and Medicinal Chemistry Sector

no actual impacts realised to date</gtr:impact><gtr:outcomeId>r-1802421660.9098220b975006</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Participants in your research or patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Production of amphotericin B analogues in vivo</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DA2B5D0B-327A-44B0-9FC2-59A4FDB97350</gtr:id><gtr:impact>25 min oral presentation at Zing Natural Products Conference, Antigua, March 1st-4th 2009.

no actual impacts realised to date</gtr:impact><gtr:outcomeId>r-1926855008.98105570ba34fd2</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Participants in your research or patient groups</gtr:primaryAudience><gtr:url>http://www1.aston.ac.uk/lhs/staff/az-index/poynerdr</gtr:url><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Combating the emergence of drug resistance</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>ED65A797-C492-4911-A15A-E91A30F8FA35</gtr:id><gtr:impact>Lecture at one-day conference in University of Birmingham 16th May 2011 (School of Biosciences).''Novel analogues of amphotericin B generated through genetic engineering of Streptomyces nodosus&amp;quot;

no actual impacts realised to date</gtr:impact><gtr:outcomeId>r-3519312873.03502940bea387a</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>In vivo production of amphotericin B analogues</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BE2FA5CC-D7D6-4715-B41F-94D620DFA4DC</gtr:id><gtr:impact>30 minute oral presentation by the grant's PDRA at 'The Chemistry and Biology of Natural Products V' University of Bristol - Wednesday Jun 17th 2009. 30 minute lecture

no actual impacts realised to date</gtr:impact><gtr:outcomeId>r-1839860521.10778210ba3ab94</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Participants in your research or patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>35</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Analogues of amphotericin B</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>Biotica Technology</gtr:fundingOrg><gtr:id>ED2D16F6-817D-4234-8BF1-C17AFC04785F</gtr:id><gtr:outcomeId>r-8207577474.608623506881666</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Analogues of amphotericin B</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>Biotica Technology</gtr:fundingOrg><gtr:id>4CF974AE-3F71-4516-B7E5-9AACB3D20CA6</gtr:id><gtr:outcomeId>5ebe27305ebe2744</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>FAFB4ED9-02F9-426E-856F-81A4765B594F</gtr:id><gtr:title>Versatility of enzymes catalyzing late steps in polyene 67-121C biosynthesis.</gtr:title><gtr:parentPublicationTitle>Bioscience, biotechnology, and biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb6a5d8549b3d538383aa12679a5a486"><gtr:id>eb6a5d8549b3d538383aa12679a5a486</gtr:id><gtr:otherNames>Stephens N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0916-8451</gtr:issn><gtr:outcomeId>54478ab7ca5f42.99073565</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AAF02BAA-F6D4-44B7-B1D2-997A34F58779</gtr:id><gtr:title>Engineered synthesis of 7-oxo- and 15-deoxy-15-oxo-amphotericins: insights into structure-activity relationships in polyene antibiotics.</gtr:title><gtr:parentPublicationTitle>Chemistry &amp; biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2aff1d0a91f6d1dd66e1d251742fc69"><gtr:id>f2aff1d0a91f6d1dd66e1d251742fc69</gtr:id><gtr:otherNames>Power P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1074-5521</gtr:issn><gtr:outcomeId>54478ab65d1df7.29664542</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA99B126-D46F-434E-A332-4C7FA6934E8C</gtr:id><gtr:title>Engineered biosynthesis of disaccharide-modified polyene macrolides.</gtr:title><gtr:parentPublicationTitle>Applied and environmental microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21b484d417616eba4d019dc6cbff4bf1"><gtr:id>21b484d417616eba4d019dc6cbff4bf1</gtr:id><gtr:otherNames>De Poire E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0099-2240</gtr:issn><gtr:outcomeId>54478ab799eee8.12955543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9036D67F-E007-4605-AA0F-9E9AB2E059CA</gtr:id><gtr:title>Redesign of polyene macrolide glycosylation: engineered biosynthesis of 19-(O)-perosaminyl-amphoteronolide B.</gtr:title><gtr:parentPublicationTitle>Chemistry &amp; biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a52c65c5ba8da0f240cc372839714e7"><gtr:id>5a52c65c5ba8da0f240cc372839714e7</gtr:id><gtr:otherNames>Hutchinson E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1074-5521</gtr:issn><gtr:outcomeId>54478ab8910a56.63977215</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D8EA149-C47A-4CEB-9CC3-1B2E05C9A7B4</gtr:id><gtr:title>Isolation and characterisation of amphotericin B analogues and truncated polyketide intermediates produced by genetic engineering of Streptomyces nodosus.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99d908d5ec2575adef600110802c9ba5"><gtr:id>99d908d5ec2575adef600110802c9ba5</gtr:id><gtr:otherNames>Murphy B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>54478ab8645d73.48068734</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAB7331D-FE2F-44E9-8710-E498195A0008</gtr:id><gtr:title>A labile point in mutant amphotericin polyketide synthases.</gtr:title><gtr:parentPublicationTitle>Biotechnology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4565dafaf87d213d5e13e790513349db"><gtr:id>4565dafaf87d213d5e13e790513349db</gtr:id><gtr:otherNames>Khan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0141-5492</gtr:issn><gtr:outcomeId>54478ab75cdaa2.02094913</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/D017270/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>